No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
11c-acetate |
Acetate |
- |
- |
- |
3件: 13, 86, 88 |
2 |
[18f]fluoro-2-deoxy-2-d-glucose |
D-glucose |
D00009 |
- |
- |
2件: 86, 88 |
3 |
Acetate |
Acetate |
- |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
4 |
Act-064992 |
- |
- |
- |
- |
4件: 85, 86, 88, 210 |
5 |
Adempas® |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
2件: 86, 88 |
6 |
Ambrisentan |
Ambrisentan |
D07077 |
1件: EDNRA |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
6件: 51, 84, 85, 86, 88, 211 |
7 |
Ambrisentan 5 mg |
Ambrisentan |
D07077 |
1件: EDNRA |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 88 |
8 |
Ammonia |
Ammonia |
D02916 |
- |
- |
1件: 88 |
9 |
Atorvastatin |
Atorvastatin |
D00258, D00887, D07474 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
17件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 160, 222, 225, 265, 271, 299 |
10 |
Barnascan |
- |
- |
- |
- |
1件: 88 |
11 |
Bay 63-2521 |
- |
- |
- |
- |
2件: 86, 88 |
12 |
Bay 63-2521 ir tablet 1.0 mg |
- |
- |
- |
- |
1件: 88 |
13 |
Bay 63-2521 ir tablet 1.5 mg |
- |
- |
- |
- |
1件: 88 |
14 |
Bay 63-2521 ir tablet 2.0 mg |
- |
- |
- |
- |
1件: 88 |
15 |
Bay 63-2521 ir tablet 2.5 mg |
- |
- |
- |
- |
1件: 88 |
16 |
Bay 63-2521 tablets 0.5 mg |
- |
- |
- |
- |
2件: 86, 88 |
17 |
Bay 63-2521 tablets 1 mg |
- |
- |
- |
- |
2件: 86, 88 |
18 |
Bay 63-2521 tablets 1.5 mg |
- |
- |
- |
- |
2件: 86, 88 |
19 |
Bay 63-2521 tablets 2 mg |
- |
- |
- |
- |
2件: 86, 88 |
20 |
Bay 63-2521 tablets 2.5 mg |
- |
- |
- |
- |
2件: 86, 88 |
21 |
Bay1237592 |
- |
- |
- |
- |
2件: 86, 88 |
22 |
Bosentan |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
9件: 13, 41, 47, 51, 84, 85, 86, 88, 210 |
23 |
Bosentan monohydrate |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
4件: 51, 84, 86, 88 |
24 |
Cysteine |
L-cysteine |
D00026, D02326 |
- |
- |
9件: 6, 13, 19, 84, 85, 88, 90, 254, 296 |
25 |
D-glucose |
D-glucose |
D00009 |
- |
- |
3件: 49, 86, 88 |
26 |
Date |
Date |
- |
- |
- |
3件: 6, 88, 113 |
27 |
Edoxaban |
Edoxaban |
D09546, D09710 |
1件: F10 |
1件: Complement and coagulation cascades |
2件: 46, 88 |
28 |
Fludeoxyglucose |
- |
- |
- |
- |
1件: 88 |
29 |
Gsk1325760 |
- |
- |
- |
- |
2件: 86, 88 |
30 |
Iodine |
Iodine |
D00108 |
- |
- |
2件: 46, 88 |
31 |
Macitentan |
Macitentan |
D10135 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
5件: 51, 85, 86, 88, 210 |
32 |
Macitentan 10 mg |
Macitentan |
D10135 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
2件: 86, 88 |
33 |
Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo [3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carb |
- |
- |
- |
- |
2件: 86, 88 |
34 |
Methyl [4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1h-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]meth |
- |
- |
- |
- |
2件: 86, 88 |
35 |
Multihance |
Gadobenic acid |
D04283, D08018 |
- |
- |
2件: 86, 88 |
36 |
N-acetyl cysteine |
L-cysteine |
D00026, D02326 |
- |
- |
5件: 13, 19, 85, 88, 296 |
37 |
Ns-304 |
- |
- |
- |
- |
3件: 70, 86, 88 |
38 |
Ns-304 placebo |
- |
- |
- |
- |
2件: 70, 88 |
39 |
Opsumit |
Macitentan |
D10135 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
2件: 86, 88 |
40 |
Opsumit® |
- |
- |
- |
- |
3件: 86, 88, 210 |
41 |
Oxygen |
Oxygen |
D00003 |
- |
- |
14件: 46, 49, 70, 84, 85, 86, 88, 90, 96, 97, 193, 226, 299, 330 |
42 |
Ph-combination therapy |
- |
- |
- |
- |
2件: 86, 88 |
43 |
Ph-monotherapy |
- |
- |
- |
- |
2件: 86, 88 |
44 |
Placebo |
- |
- |
- |
- |
20件: 3, 6, 13, 14, 40, 46, 49, 50, 51, 66, 67, 79, 85, 86, 88, 96, 97, 144, 149, 226 |
45 |
Riociguat |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
6件: 51, 84, 86, 88, 225, 299 |
46 |
Riociguat (adempas, bay63-2521) |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
3件: 51, 86, 88 |
47 |
Ro 47-0203 |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
4件: 51, 85, 86, 88 |
48 |
Selexipag |
Selexipag |
D09994 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
5件: 51, 70, 84, 86, 88 |
49 |
Thrombin |
Thrombin |
D00090 |
- |
- |
2件: 86, 88 |
50 |
Tracleer |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
8件: 13, 51, 84, 85, 86, 88, 210, 211 |
51 |
Treprostinil |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
5件: 51, 84, 85, 86, 88 |
52 |
Treprostinil sodium |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
2件: 86, 88 |
53 |
Volibris |
Ambrisentan |
D07077 |
1件: EDNRA |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
3件: 51, 86, 88 |
54 |
Warfarin |
Warfarin |
D00564, D01280, D08682 |
2件: NQO1, VKORC1 |
5件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis |
10件: 6, 8, 13, 19, 46, 49, 66, 85, 88, 96 |